European Union. European Commission

European Union

Merck's VAXNEUVANCE Receives Expanded Indication Approval in the European Union for Prevention of Pneumococcal Disease

The European Commission has approved an expanded indication for Merck's (NYSE: MRK) VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) to include active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae (S. pneumoniae) in infants, children, and adolescents from 6 weeks to less